CompletedNCT06115603
Cannabigerol compared with placebo for ADHD symptoms
About this title
Read the official source — NCT06115603Medication studyAges 18–55United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- FayettevilleSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: December 14, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 76
- Sponsor
- University of Arkansas, Fayetteville
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT06115603
- Official title
Show the full official title
CBG and Attention: A Double-Blind, Randomized, Placebo-Controlled Trial Examining the Effects of Cannabigerol on Indicators of Attention-Deficit/Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Fayetteville
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Arkansas, Fayetteville, a university.
Did this study involve medication?
Yes. The study involved medication, including Cannabigerol.
Who was this study for?
Listed age limits: 18 years to 55 years.
